Access Update – #10

I hope you’ll pardon the brief update this week, but it’s 1:15 a.m. and I’m in my hotel room putting the finishing touches on my speech for the 13th Annual Pharma & Biotech Licensing & Deal Making Summit. There are some heavy hitters here including the heads of business development from several large-cap pharmaceutical and biotech companies, as well as one of the world’s leading authorities on monoclonal antibodies.

I did want to let you know about a time change for our upcoming conference call. The call will be moved up one half hour to 12:30 p.m. ET/9:30 a.m. PT on Wednesday, May 28. The earlier start time is to accommodate our independent expert who will be calling in from Israel.

The report on this company should be out next week, so keep an eye on your inboxes.

Meanwhile, I’d like to address a question I received this week from a subscriber.

Q: In a follow-up to your recent update I did purchase MELA at $6.00. Should I sell now, take the profits and wait for it to come back down, subsequently buying it back below 5.75?

A: It’s important to note that we are not permitted to give personalized advice. When we believe that it’s time to take partial or total profits, we’ll send out an alert. We’re in this story for the long term and are not recommending selling any positions yet.

Meanwhile, the stock continues to hang around the $7 area. We continue to believe the stock will come in and will give investors a chance to buy at our limit price of $5.75.

Have a great weekend and keep an eye out for our new recommendation.

Marc Lichtenfeld
Director of Research
Access Research Group

Stock
Symbol
Current Price
Comments

Electro-Optical Sciences

MELA

$7.27

Buy up to $5.75